Clinical Trial Update: AL Amyloidosis and Anti-CD38-Daratunumab [NA]

View source ↗

Summary

Completed clinical trial evaluating daratumumab, an anti-CD38 antibody, for AL amyloidosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: University of Turin, Italy | Conditions: Amyloidosis | NA | Status: COMPLETED